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Abstract

Results

Discussion

Stroke is the leading cause of disability and second most common
cause of death worldwide. Ischemic stroke accounts for 80% of all
strokes, and are the result of the blood supply to the brain being
interrupted abruptly. Atheroembolism, or a cholesterol embolism, is
a major contributor to ischemic strokes. Due to this fact, treatment
of carotid artery stenosis has been aimed at preventing
atheroembolization by controlling plaque buildup in arteries before
they have the chance to break off and cause harm. In an attempt to
prevent future stroke (O) in adult patients with asymptomatic
carotid artery disease (P), will performing a carotid endarterectomy
(I) compared to carotid stent placement (C) have lower associated
risks (O)?

The literature review and critique showed there currently is no real
statistical difference in the outcomes related to carotid
endarterectomy versus carotid artery stenosis in the treatment
prevention of stroke in patients with asymptomatic carotid stenosis.
Two randomized controlled trials, the ACT-1 and 10-year follow-up
to CREST-1, both showed no significant difference between the two
interventions. All retrospective cohort studies came to the same
conclusion as the RCTs, with the exception of one that found CAS to
be significantly higher risk than CEA in the prevention of
periprocedural stroke and death. Overall, every patient is different
and as of now it is up to the patient and clinical team to decide
which is best for the individual based on their health and risks they
are willing to take.

Most of the studies focused on periprocedural outcomes in the form
of ipsilateral stroke, myocardial infarction, and in-hospital death, as
well as later outcomes. One study broke down outcomes further
into secondary outcomes including: cranial/peripheral nerve injury,
noncerebral bleeding, would complications, and other. The definition
of “later outcome” varied depending on the study (30-days, 1
month, every 6 months, 4 years, 7 years, 10 years). There were
some differences in patient populations studied, which was
uncontrollable due to the nature of the retrospective cohort studies
being the majority of studies available. There was also some
difference in the medical treatment provided before and after
procedures. Overall, the studies found that neither CEA or CAS are
inferior to the other.

Table 1. Comparison of Results

Thankfully, there are currently three randomized controlled trials
that are ongoing and will hopefully give us more clarity in the
future:

Introduction
Stroke Overview:

Study

Periprocedural
Stroke

Periprocedural In-Hospital
1-Yr
MI
Death
Stroke-Free

1-Yr
Survival

Brott et al
(2016)

S

Choi et al
(2015)

S

NS

S

N/A

N/A

Mazzaccaro
et al
(2019)

NS

S

NS

NS

NS

Rizwan et al
(2019)

NS

Result of interruption of blood supply to the brain
Ischemic (80%) vs. hemorrhagic
15-20% of ischemic strokes are related to carotid artery stenosis
(CAS)
Carotid Artery Stenosis:
Atheroembolization – ruptured atherosclerotic plaque travels to more
distal/smaller arteries resulting in blockage
Known to be the cause of ischemic strokes related to the carotid
artery (rather than carotid occlusion)
CAS further broken down into:
Symptomatic – aphasia, dysphasia, impairment or loss of vision in
ipsilateral eye, TIA, or amaurosis fugax in the past 6 months
Asymptomatic – stenosis with no symptoms
Treatment:
Aimed at controlling/reducing plaque buildup before it has the chance
to rupture
Three mechanisms:
Best Medical Therapy (BMT) – Biological
Carotid Endarterectomy (CEA) – Surgical

S

S

NS

NS

NS

NS

NS

NS

Asymptomatic
Carotid Surgery
Trial-2
(ACST-2)

Carotid
Revascularization
and Medical
Management for
Asymptomatic
Carotid Stenosis
Trial-2

• Follow-up to ACST-1 (1993-2003)
• International RCT coordinated by The ACST-2 office at The University of Oxford
• Jan 2008 to Dec 2020
• CEA vs. CAS for long-term stroke prevention
• n = 3,638
• Results expected late 2021

• Follow-up to CREST (2000-2011)
• Multi-center RCT sponsored by the National Institute of Neurological Disorders
and Stroke of the National Institutes of Health
• Dec 2014 to est. Dec 2022
• BMT alone vs. BMT/CEA vs. BMT/CAS
• Est. n = 2,480
• Study is currently ongoing

(CREST-2)

Rosenfield et
al
(2016)

NS

Sharma et al
(2019)

N/A

NS

NS

N/A

N/A

Key: S – significant; NS – not significant; N/A – not applicable

NS

NS

NS

NS

European Carotid
Surgery Trial-2
(ESCT-2)

• International RCT initially funded by the National Institute for Health Research,
currently funded by the Stroke Association, UK
• Initiated in March of 2012
• Comparing optimized medical treatment (OMT) alone vs. OMT/CEA vs.
OMT/CAS in both symptomatic and asymptomatic patients
• n = 2,000
• Study is currently ongoing

Carotid Artery Stenting (CAS) – Surgical

Based on randomized controlled trials (RCTs) and evidence-based
procedures, CEA has been shown to be the treatment of choice for
symptomatic patients with 50-99% stenosis. But what about
asymptomatic patients?

Methods
A literature search was conducted through PubMed, Clinical Key, and
Academic Search Premier in November of 2019. Six articles were
selected based on patient population, publication date, study design
and interventions compared.

Conclusion
BMT
CAS
CEA

Carotid artery stenting and carotid endarterectomy are not superior
to one another, and choice should be based individually per patient.
Both have low morbidity and low mortality rates. Given the lack of
randomized controlled trials for this specific patient population,
there needs to be more research done before a definitive answer
can be given to this research question. Currently there are at least
three ongoing trials that aim to determine a more definitive answer.
These trials are set to end in the next 2 years.

